Benzinga's Microcap Movers for Thursday July 5, 2012
Below are highlights from Benzinga's daily coverage of small cap and microcap securities making big moves:
Shares of Savient Pharmaceuticals (NASDAQ: SVNT), the East Brunswick, biopharmaceutical company, rose 16.00% Thursday on 1.4 times the average daily volume.
Savient announced Monday a new publication showing that adult patients with refractory chronic gout treated bi-weekly with KRYSTEXXA experienced statistically significant and clinically meaningful improvements in health-related quality of life, pain and physical function. The results were published in the print edition of the July 2012 issue of The Journal of Rheumatology.
Savient Pharmaceuticals closed at $0.58 on Thursday.
Shares of Rexahn Pharmaceuticals (NYSE: RNN), the Rockville, MD biopharmaceutical company, rose 25.00% Thursday on 10 times average volume.
Rexahn Pharmaceuticals announced Monday that it had submitted an investigational new drug application to the Food and Drug Administration for a first-in-human study of RX-5902 to treat advanced or metastatic solid tumors. RX-5902 is a first-in-class small molecule that inhibits the phosphorylated p68 RNA helicase, a protein that plays a key role in cancer growth, progression and metastasis. The phosphorylated form of p68 RNA helicase is only present in cancer cells and is absent in normal cells.
Rexahn Pharmaceuticals closed at $0.53 on Thursday.
Standard Register Company
Shares of Standard Register Company (NYSE: SR), the Dayton, OH provider of services to the healthcare industry, rose 9.39% Thursday on average volume.
Standard Register Company received an upgrade from CJS Securities Thursday to Outperform.
Standard Register Company closed at $0.70 on Thursday.
The information in this article is taken from public sources, press releases, and websites that cannot always be verified. Please note that investing in microcap stocks is highly speculative. The companies mentioned here are for information purposes only. Benzinga makes no claim as to the suitability of these stocks as an investment. Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.